FDA Rush To Meet Pediatric Statutory Deadline Compromised Policy - Lawsuit
This article was originally published in The Tan Sheet
FDA's push to meet statutory deadlines set for the FDA Modernization Act pediatric exclusivity provision short-changed public input and resulted in too broad a drug list for which innovator companies may gain exclusivity, generic groups assert in a lawsuit filed in D.C. federal court Feb. 19.
You may also be interested in...
Perrigo promotes in pricing, planning
Combe sells most of its OTC brands
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC